BibTex format
@article{Dejnirattisai:2022:10.1016/j.cell.2021.12.046,
author = {Dejnirattisai, W and Huo, J and Zhou, D and Zahradník, J and Supasa, P and Liu, C and Duyvesteyn, HME and Ginn, HM and Mentzer, AJ and Tuekprakhon, A and Nutalai, R and Wang, B and Dijokaite, A and Khan, S and Avinoam, O and Bahar, M and Skelly, D and Adele, S and Johnson, SA and Amini, A and Ritter, TG and Mason, C and Dold, C and Pan, D and Assadi, S and Bellass, A and Omo-Dare, N and Koeckerling, D and Flaxman, A and Jenkin, D and Aley, PK and Voysey, M and Costa, Clemens SA and Naveca, FG and Nascimento, V and Nascimento, F and Fernandes, da Costa C and Resende, PC and Pauvolid-Correa, A and Siqueira, MM and Baillie, V and Serafin, N and Kwatra, G and Da, Silva K and Madhi, SA and Nunes, MC and Malik, T and Openshaw, PJM and Baillie, JK and Semple, MG and Townsend, AR and Huang, K-YA and Tan, TK and Carroll, MW and Klenerman, P and Barnes, E and Dunachie, SJ and Constantinides, B and Webster, H and Crook, D and Pollard, AJ and Lambe, T and OPTIC, Consortium and ISARIC4C, Consortium},
doi = {10.1016/j.cell.2021.12.046},
journal = {Cell},
pages = {467--484.e15},
title = {SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses},
url = {http://dx.doi.org/10.1016/j.cell.2021.12.046},
volume = {185},
year = {2022}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.
AU - Dejnirattisai,W
AU - Huo,J
AU - Zhou,D
AU - Zahradník,J
AU - Supasa,P
AU - Liu,C
AU - Duyvesteyn,HME
AU - Ginn,HM
AU - Mentzer,AJ
AU - Tuekprakhon,A
AU - Nutalai,R
AU - Wang,B
AU - Dijokaite,A
AU - Khan,S
AU - Avinoam,O
AU - Bahar,M
AU - Skelly,D
AU - Adele,S
AU - Johnson,SA
AU - Amini,A
AU - Ritter,TG
AU - Mason,C
AU - Dold,C
AU - Pan,D
AU - Assadi,S
AU - Bellass,A
AU - Omo-Dare,N
AU - Koeckerling,D
AU - Flaxman,A
AU - Jenkin,D
AU - Aley,PK
AU - Voysey,M
AU - Costa,Clemens SA
AU - Naveca,FG
AU - Nascimento,V
AU - Nascimento,F
AU - Fernandes,da Costa C
AU - Resende,PC
AU - Pauvolid-Correa,A
AU - Siqueira,MM
AU - Baillie,V
AU - Serafin,N
AU - Kwatra,G
AU - Da,Silva K
AU - Madhi,SA
AU - Nunes,MC
AU - Malik,T
AU - Openshaw,PJM
AU - Baillie,JK
AU - Semple,MG
AU - Townsend,AR
AU - Huang,K-YA
AU - Tan,TK
AU - Carroll,MW
AU - Klenerman,P
AU - Barnes,E
AU - Dunachie,SJ
AU - Constantinides,B
AU - Webster,H
AU - Crook,D
AU - Pollard,AJ
AU - Lambe,T
AU - OPTIC,Consortium
AU - ISARIC4C,Consortium
AU - Paterson,NG
AU - Williams,MA
AU - Hall,DR
AU - Fry,EE
AU - Mongkolsapaya,J
AU - Ren,J
AU - Schreiber,G
AU - Stuart,DI
AU - Screaton,GR
DO - 10.1016/j.cell.2021.12.046
EP - 484
PY - 2022///
SN - 0092-8674
SP - 467
TI - SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
T2 - Cell
UR - http://dx.doi.org/10.1016/j.cell.2021.12.046
UR - https://www.ncbi.nlm.nih.gov/pubmed/35081335
UR - http://hdl.handle.net/10044/1/94557
VL - 185
ER -
